SI
KYNB

Sofinnova Investments’s Kyntra Bio KYNB Stock Holding History

Sofinnova Investments’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,000
Closed -$1.75M – 72
2023
Q2 		$1.75M Buy
+26,000
New +$10.8M 0.11% 43
2021
Q3 		– Sell
-8,000
Closed -$5.33M – 78
2021
Q2 		$5.33M Buy
+8,000
New +$4.61M 0.31% 48
2019
Q2 		– Sell
-2,000
Closed -$2.72M – 77
2019
Q1 		$2.72M Buy
+2,000
New +$2.71M 0.26% 54

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sofinnova Investments's KYNB Position: Q3 2023 in Review

Sofinnova Investments sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 25,503 shares — an estimated $1.72M sold.

Sofinnova Investments first reported a position in KYNB in Q4 2018 and held it in 3 quarters. The position peaked at $3.7M in Q4 2018. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Sofinnova Investments reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Sofinnova Investments sold 25,503 Kyntra Bio shares in Q3 2023, an estimated $1.72M.
  • Sofinnova Investments first reported a position in Kyntra Bio in Q4 2018 and held it in 3 quarters.
  • Sofinnova Investments's Kyntra Bio position peaked at $3.7M in Q4 2018.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Sofinnova Investments's 13F filing for Q3 2023, filed 14 Nov 2023.